Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer

BJU International

Volumn 104, Issue 11, 2009, Pages 1592-1598

  Moore, Alison L ^a   Dimitropoulou, Polyxeni ^a   Lane, Athene ^b   Powell, Philip H ^c   Greenberg, David C ^d   Brown, Clement H ^d   Donovan, Jenny L ^b   Hamdy, Freddie C ^d   Martin, Richard M ^b   Neal, David E ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c FREEMAN HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Clinical stage; Community based PSA testing; Early detection; Gleason grade; Prostate cancer; ProtecT study; PSA; Treatments; Urinary symptoms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ANTIGEN DETECTION; ARTICLE; BLOOD LEVEL; CANCER GRADING; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER REGISTRY; CANCER SCREENING; CANCER STAGING; CANCER TEST; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENERAL PRACTITIONER; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TUMOR BIOPSY; UNITED KINGDOM;

AGED; EARLY DETECTION OF CANCER; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 70350690484     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08652.x     Document Type: Article

References (46)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001 37 (Suppl. 8 S4 66
2. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000 85 : 60 7
3. Oliver SE, May MT, Gunnell D. International trends in prostate-cancer mortality in the 'PSA ERA'. Int J Cancer 2001 92 : 893 898
4. Bartsch G, Horninger W, Klocker H et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol. Austria Urol 2001 58 : 417 424
5. Farkas A, Schneider D, Perrotti M, Cummings KB, Ward WS. National trends in the epidemiology of prostate cancer, 1973-94: evidence for the effectiveness of prostate-specific antigen screening. Urology 1998 52 : 444 448
6. Mettlin CJ, Murphy GP. Why is the prostate cancer death rate declining in the United States? Cancer 1998 82 : 249 251
7. Frankel S, Smith GD, Donovan J, Neal D. Screening for prostate cancer. Lancet 2003 361 : 1122 1128
8. Martin RM, Smith GD, Donovan J. Does current evidence justify prostate cancer screening in Europe? Nat Clin Pract Oncol 2005 2 : 538 539
9. Donovan JL, Martin RM, Neal DE, Hamdy FC. Prostate cancer: screening approaches. Br J Hosp Med (Lond) 2005 66 : 623 626
10. Parker C, Muston D, Melia J, Moss S, Dearnaley D. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 2006 94 : 1361 1368
11. McGregor M, Hanley JA, Boivin JF, McLean RG. Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 1998 159 : 1368 1372
12. Draisma G, Boer R, Otto SJ et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003 95 : 868 878
13. Etzioni R, Legler JM, Feuer EJ, Merrill RM, Cronin KA, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer - part III. Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999 91 : 1033 1039
14. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002 325 : 740
15. Oliver SE, Gunnell D, Donovan JL. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 2000 355 : 1788 1789 (Pubitemid 30265086)
16. Shibata A, Ma J, Whittemore AS. Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst 1998 90 : 1230 1231
17. Coldman AJ, Phillips N, Pickles TA. Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity. CMAJ 2003 168 : 31 5
18. Shaw PA, Etzioni R, Zeliadt SB et al. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am J Epidemiol 2004 160 : 1059 1069
19. Collin SM, Martin RM, Metcalfe C et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 2008 9 : 445 452
20. Etzioni R, Tsodikov A, Mariotto A et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control 2008 19 : 175 181
21. Donovan J, Martin R. Commentary: screening for prostate cancer. Int J Epidemiol 2007 36 : 30
22. Andriole GL, Levin DL, Crawford ED et al. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005 97 : 433 438
23. de Koning HJ, Auvinen A, Berenguer Sanchez A et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer 2002 97 : 237 244
24. Wilt TJ. SPCG-4: a needed START to PIVOTal data to promote and protect evidence-based prostate cancer care. J Natl Cancer Inst 2008 100 : 1123 1125
25. Wilt TJ, Brawer MK, Barry MJ et al. The Prostate cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program 407 (PIVOT). design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials 2009 30 : 81 7
26. Grubb RL III, Pinsky PF, Greenlee RT et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int 2008 102 : 1524 1530
27. Melia J, Moss S, Johns L. Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int 2004 94 : 51 6
28. Donovan J, Mills N, Smith M et al. Quality improvement report. Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult. BMJ 2002 325 : 766 770
29. Donovan JL, Peters TJ, Noble S et al. Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study). J Clin Epidemiol 2003 56 : 605 609
30. Mills N, Donovan JL, Smith M, Jacoby A, Neal DE, Hamdy FC. Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study. Control Clin Trials 2003 24 : 272 282
31. Office for National Statistics GR Of S. Northern Ireland Statistics and Research Agency. Mid-2005 Population Estimates: UK. 2006. Available at: http://www.statistics.gov.uk/statbase/explorer.asp?CTG=3&SL=4819,4784&D= 4949&DCT=32&DT=32#4949. Accessed June 2007
32. Brenner H, Arndt V. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis. J Clin Oncol 2005 23 : 441 447
33. Chamberlain J, Melia J, Moss S, Brown J. Report prepared for the Health Technology Assessment panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales. Br J Urol 1997 79 (Suppl. 3 1 32
34. Loblaw DA, Virgo KS, Nam R et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007 25 : 1596 1605
35. Eeles RA, Kote-Jarai Z, Giles GG et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008 40 : 316 321
36. Postma R, van Leenders AG, Roobol MJ, Schroder FH, van der Kwast TH. Tumour features in the control and screening arm of a randomized trial of prostate cancer. Eur Urol 2006 50 : 70 5
37. Etzioni R, Penson DF, Legler JM et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002 94 : 981 990
38. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005 293 : 2095 2101 (Pubitemid 40617061)
39. Bill-Axelson A, Holmberg L, Filen F et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008 100 : 1144 1154
40. Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005 352 : 1977 1984 (Pubitemid 40638368)
41. Kranse R, Beemsterboer P, Rietbergen J, Habbema D, Hugosson J, Schroder FH. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region). Prostate 1999 39 : 316 322 (Pubitemid 29244508)
42. Beemsterboer PM, Kranse R, de Koning HJ, Habbema JD, Schroder FH. Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam). Int J Cancer 1999 84 : 437 441 (Pubitemid 29337134)
43. Schröder FH, Roobol MJ, Tammela TL et al. ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009 360 : 1320 1328
44. Andriole GL, Buys SS, Chia D et al. PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009 360 : 1310 1319
45. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005 23 : 8165 8169
46. Roemeling S, Roobol MJ, de Vries SH et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 2007 51 : 1244 1250